NBDF recently learned that Novo Nordisk now has 3,000 IU vial size of Rebinyn® back in stock. Rebinyn is the company's recombinant factor IX extended half-life therapy for the treatment of hemophilia B. It is indicated for the on-demand treatment and control of bleeding episodes and the management of bleeding around surgery. It is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes.
Novo Nordisk had reported a temporary shortage of the 3,000 IU vial size this past winter.
There is now an adequate supply of all vial sizes, including 500 IU, 1000 IU, 2000 IU and 3000 IU. Read the full prescribing information for Rebinyn.
Please contact your healthcare provider with questions. You may also reach the Novo Nordisk Customer Care line by calling 1.800.727.6500.
Supplemental Resources-
Learn more about hemophilia B.
Read MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Selected Disorders of the Coagulation System
Access a comprehensive list of all FDA-approved therapies to treat bleeding disorders
Source: Novo Nordisk
